Recurrent Ovarian Adenocarcinoma
1 clinical trials · Condition
◉ Watch Recurrent Ovarian Adenocarcinoma
| Record | Firm | Date |
|---|---|---|
| Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer (NCT06393751) | National Cancer Institute (NCI) | 2025-10-31 |
Track Recurrent Ovarian Adenocarcinoma automatically
Every clearance here is in the API, with alerts when new ones post.